Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Active not recruiting 3Recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 4Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 17Myelodysplastic Syndromes 9Leukemia, Myelomonocytic, Chronic 4Myeloproliferative Disorders 3Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Biphenotypic, Acute 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Primary Myelofibrosis 1Polycythemia Vera 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Hodgkin Disease 1GATA2 Deficiency 1Cytopenia 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1BRCA1 Mutation 1Anemia, Refractory, with Excess of Blasts 1Allogeneic Stem Cell Transplantation 1

Interventions

Azacitidine 12Cyclophosphamide 10venetoclax 8fludarabine phosphate 7fludarabine 7Whole-Body Irradiation 7Biopsy 7Specimen Handling 6Mycophenolic Acid 6Injections 6Decitabine 6Tacrolimus 5Cytarabine 5Busulfan 5decitabine and cedazuridine drug combination 4Stem Cell Transplantation 4Peripheral Blood Stem Cell Transplantation 4Cyclosporine 4cedazuridine 3X-Rays 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3olutasidenib 2Vorinostat 2Sirolimus 2Rituximab 2Melphalan 2Magnetic Resonance Spectroscopy 2Lenalidomide 2Idarubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Chronic × decitabine and cedazuridine drug combination × 90 days × Clear all
NCT03613532 2026-05-20

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
102 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT04980404 2026-03-30

Inqovi Maintenance Therapy in Myeloid Neoplasms

Massachusetts General Hospital

Phase 1 Active not recruiting
22 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelomonocytic, Chronic

NCT05636514 2026-03-18

CELESTIAL-MDS

Clinical Hub for Interventional Research (CHOIR)

Phase 1 Recruiting
12 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡